Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: A five-year summary from the SENTRY Antimicrobial Surveillance Program (1997-2001)

Seminars in Respiratory and Critical Care Medicine

Volumn 24, Issue 1, 2003, Pages 121-133

  Jones, Ronald N ^a,b  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibiotics; Empirical therapy; Nosocomial infections; Resistance; SENTRY; Surveillance

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CEFEPIME; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; DALFOPRISTIN PLUS QUINUPRISTIN; DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; IMIPENEM; LINEZOLID; MEROPENEM; OXACILLIN; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; PSEUDOMONIC ACID; TEICOPLANIN; TOBRAMYCIN; VANCOMYCIN;

ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; BACTERIUM ISOLATION; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; INFECTION CONTROL; INTENSIVE CARE UNIT; MULTIDRUG RESISTANCE; PATHOGENESIS; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SOFT TISSUE INFECTION; URINARY TRACT INFECTION;

EID: 0037325617     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-37923     Document Type: Review

References (79)

1. Jones RN. Resistance patterns among nosocomial pathogens, trends over the past few years. Chest 2001;119:397S-404S
2. Weinstein RA. Nosocomial infection update. Emerg Infect Dis 1998;4:416-420
3. Public Health Initiative Research Institute. Report from the Bacterial Antibiotic Resistance Group/Infectious Disease Center. Washington, DC: U.S. Government Printing Office; 1997
4. US Department of Health and Human Services. Addressing emerging infectious disease threats: A prevention strategy for the United States. Washington, DC:U.S. Government Printing Office; 1994
5. Impacts of antibiotic-resistant bacteria: thanks to penicillin, he will come home! Washington, DC: Office of Technology Assessment; 1995. Publication OTA-H-629
6. Phelps CE. Bug-drug resistance: sometimes less is more. Med Care 1989;27:194-203
7. Ibrahim EH, Sherman G, Ward W, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of blood stream infections on patient outcomes in the ICU setting. Chest 2000;118:146-155
8. Kollef MH. Antimicrobial therapy of ventilator-associated pneumonia. Chest 1999;115:8-11
9. Jones RN. The emergent needs for basic research, education, and surveillance of antimicrobial resistance: problems facing the report from the American Society for Microbiology Task Force on Antimicrobial Resistance. Diagn Microbiol Infect Dis 1996;25:153-161
10. Bax R, Bywater R, Cornaglia G, et al. Surveillance of antimicrobial resistance: what, how and whither? Clin Microbiol Infect 2001;7:316-325
11. Jones RN, Masterton R. Determining the value of antimicrobial surveillance programs. Diagn Microbiol Infect Dis 2001;41:171-175
12. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 5th ed. Approved standard M7-A5. Wayne, PA: NCCLS; 2000
13. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. 12th informational supplement M100-S12. Wayne, PA: NCCLS; 2002
14. Turner PJ, Greenhalgh JM, Edwards JR, McKellar J. The MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) Programme. Int J Antimicrob Agents 1999;13:117-125
15. Global aspects of antimicrobial resistance among key bacterial pathogens: results from the 1997-1999 SENTRY Antimicrobial Surveillance Program. Clin Infect Dis 2001; 32(suppl 2):S81-S167
16. Pfaller MA, Jones RN, Doern GV, et al. Bacterial pathogens isolated from patients with blood stream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada). Antimicrob Agents Chemother 1998;42:1762-1770
17. Pfaller MA, Jones RN, Doern GV, et al. Survey of blood stream infections due to gram-positive cocci: frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 1999;33:283-297
18. Diekema DJ, Pfaller MA, Jones RN, et al, and the SENTRY Participants Group. Trends in antimicrobial susceptibility of bacterial pathogens isolated from patients with blood stream infections in the USA, Canada and Latin America. Int J Antimicrob Agents 2000;13:257-271
19. Moet G, Biedenbach D, Pfaller M, Jones RN. 2002. Occurrence of blood stream infection (BSI) pathogens and key resistances (R) from the SENTRY Antimicrobial Surveillance Program, a 5-year report [abstract C2-299]. In: Programs and Abstracts of the 42nd Interscience Congress of Antimicrobial Agents and Chemotherapy. American Society for Microbiology, San Diego, CA
20. Diekema DJ, Pfaller MA, Jones RN, and the SENTRY Participants Group. Age-related trends in pathogen frequency and antimicrobial susceptibility of blood stream isolates in North America: SENTRY Antimicrobial Surveillance Program, 1997-2000. Int J Antimicrobial Agents 2002;20:412-418
21. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in pediatric intensive care units in the United States. Pediatrics 1999;103:39-46
22. Villari P, Sarnataro C, Iacuzio L. Molecular epidemiology of Staphylococcus epidermidis in a neonatal intensive care unit over a three-year period. J Clin Microbiol 2000;38:1740-1746
23. Mathai D, Lewis MT, Kugler KC, Pfaller MA,Jones RN, and the SENTRY Participants Group (North America). Antibacterial activity of 41 antimicrobials tested against over 2773 bacterial isolates from hospitalized patients with pneumoniae, I: Results from the SENTRY Antimicrobial Surveillance Program (North America, 1998). Diagn Microbiol Infect Dis 2001;39:105-116
24. The SENTRY Participants Group (Latin America), Lewis MT, Gales AC, Sader HS, Pfaller MA, Jones RN. Frequency of occurrence and antimicrobial susceptibility patterns for pathogens isolated from Latin American patients with a diagnosis of pneumonia: results from the SENTRY Antimicrobial Surveillance Program (1998). Diagn Microbiol Infect Dis 2000;37:63-74
25. Kirby JT, Mutnick AH, Jones RN. Biedenbach DJ, Pfaller MA, and the SENTRY Participants Group. Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000). Diagn Microbiol Infect Dis 2002;43:303-309
26. Mathai D, Jones RN, Pfaller MA, and the SENTRY Participant Group, North America. Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1510 hospitalized patients: a report from the SENTRY Antimicrobial Surveillance Program (North America). Diagn Microbiol Infect Dis 2001;40:129-136
27. Jones RN, Kugler KC, Pfaller MA, Winokur PL, and the SENTRY Surveillance Group, North America. Characteristics of pathogens causing urinary tract infections in hospitals in North America: results from the SENTRY Antimicrobial Surveillance Program, 1997. Diagn Microbiol Infect Dis 1999;35:55-63
28. Gales AC, Gordon KA, Wilke WW, Pfaller MA, Jones RN. Occurrence of single-point gyr A mutations among ciprofloxacin-susceptible Escherichia coli isolates causing urinary tract infections in Latin America. Diagn Microbiol Infect Dis 2000;36:61-64
29. Jones RN, Beach ML, Pfaller MA. Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas, 2000): More alike than different! Diagn Microbiol Infect Dis 2001;41:161-163
30. Stephen J, Mutnick A, Jones RN. Assessment of pathogens and resistance (R) patterns among intensive care unit (ICU) patients in North America (NA): initial report from the SENTRY Antimicrobial Surveillance Program (2001). Abstract C2-297. In: Programs and Abstracts of the 42nd Interscience Congress of Antimicrobial Agents and Chemotherapy. American Society for Microbiology, San Diego, CA. 2002
31. Garcia-Rodriguez J-A, Jones RN, and the MYSTIC Programme Study Group. Antimicrobial resistance in gramnegative isolates from European intensive care units: data from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme. J Chemother 2002;14:25-32
32. CDC NNIS System. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1990-May 1999, issued June 1999. Am J Infect Control 1999;27:520-532
33. Centers for Disease Control and Prevention. Update: Staphylococcus aureus with reduced susceptibility to vancomycin. United States, 1997. Morb Mortal Wkly Rep 1997;46:813-815
34. Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997;350:70-73
35. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997;40:135-146
36. Centers for Disease Control. Staphylococcus aureus resistant to vancomycin. United States, 2002. Morb Mortal Wkly Rep 2002;51:565-567
37. Tsiodras S, Godl HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001;358:207-208
38. Mutnick A, Jones RN, Rhomberg P, Moet G. Oxazolidinone (OXA)-resistant (R) enterococci emerging in 2001: report patients from the SENTRY Antimicrobial Surveillance Program (USA) [abstract C2-288]. In: Programs and Abstracts of the 42nd Interscience Congress of Antimicrobial Agents and Chemotherapy. American Society for Microbiology, San Diego, CA. 2002
39. Malbruny B, Canu A, Bozdogan B, et al. Resistance to quinupristin/dalfopristin due to mutation of L22 ribosomal protein in Staphylococcus aureus. Antimicrob Agents Chemother 2002;46:2200-2207
40. Deshpande LM, Fix AM, Pfaller MA, the SENTRY Antimicrobial Surveillance Program Participants Group, Jones RN. Emerging elevated mupirocin resistance rates among staphylococcal isolates in the SENTRY Antimicrobial Surveillance Program (2000): correlations of results from disk diffusion, Etest and reference dilution methods. Diagn Microbiol Infect Dis 2002;42:283-290
41. Rhomberg P, Jones RN, Mutnick A.Geographic variations and trends in key bacteremic pathogen resistance (R): report from the SENTRY Antimicrobial Surveillance Program (1997-2001) [abstract C2-298]. In: Programs and Abstracts of the 42nd Interscience Congress of Antimicrobial Agents and Chemotherapy. American Society for Microbiology, San Diego, CA. 2002
42. Ike Y, Arakawa Y, Ma X, et al. Nationwide survey shows that methicillin-resistant Staphylococcus aureus strains heterogeneously and intermediately resistant to vancomycin are not disseminated throughout Japanese hospitals. J Clin Microbiol 2001;39:4445-4451
43. Schwalbe RS, Stapleton JT, Gilligan PH. Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med 1987;316:927-931
44. Diekema DJ, Jones RN. Oxazolidinone antibiotics. Lancet 2001;358:1975-1982
45. Mutnick AH, Biedenbach DJ, Turnidge JD, Jones RN. Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000. Diagn Microbiol Infect Dis 2002;43:65-73
46. Gonzales RD, Schreckenberger PC, Graham MG, Kelkar S, Den-Besten K, Quinn JP. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 2001;357:1179-1182
47. Jones RN, Della-Latta PH, Lee LV, Biedenbach DJ. Linezolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2002;42:137-139
48. Huycke MM, Sahm DF, Gilmore MS. Multiple-drug resistant enterococci: the nature of the problem and an agenda for the future. Emerg Infect Dis 1998;4:239-249
49. Centers for Disease Control. Nosocomial enterococci resistant to vancomycin: United States, 1989-1993: National Nosocomial Infections Surveillance. Morb Mortal Wkly Rep 1993;42:597-599
50. Low DE, Keller N, Barth A, Jones RN. Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001; 32(suppl 2):S133-S145
51. Carmeli Y, Eliopoulos GM, Samore MH. Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant Enterococcus. Emerg Infect Dis 2002;8:802-804
52. Mallon DJP, Corkill JE, Hazel SM, et al. Excretion of vancomycin-resistant enterococci by wild mammals. Emerg Infect Dis 2002;8:636-638
53. Hoban DJ, Doern GV, Fluit AC, Roussel-Delvallez M, Jones RN. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001;32(suppl 2):S81-S93
54. Jones RN, Pfaller MA. Macrolide and fluoroquinolone (levofloxacin) resistances among Streptococcus pneumoniae strains: significant trends from the SENTRY Antimicrobial Surveillance Program (North America, 1997-1999). J Clin Microbiol 20002;38:4298-4299
55. Roson B, Carratala J, Tubau F, et al. Usefulness of β-lactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin/clavulanic and ceftriaxone. Microb Drug Resist 2001;7:85-96
56. Jones RN, Pfaller MA. Letter to the Editor. Potencies of newer fluoroquinolones against viridans group streptococci isolated in 637 cases of blood stream infection in the SENTRY Antimicrobial Surveillance Program (1997 to 1999): beyond Canada! Antimicrob Agents Chemother 2000;44:2922-2923
57. Gordon KA, Beach ML, Biedenbach DJ, Jones RN, Rhomberg PR, Mutnick AH. Antimicrobial susceptibility patterns of β-haemolytic and viridans group streptococci: report from the SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn Microbiol Infect Dis 2002;43:157-162
58. Winokur PL, Canton R, Casellas J-M, Legakis N. Variations in the prevalence of strains expressing an extended-spectrum β-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. Clin Infect Dis 2001;32(suppl 2):S94-S103
59. Jones RN, Baquero F, Privitera G, Inoue M, Wiedemann B. Inducible β-lactamase-mediated resistance to third-generation cephalosporins. Clin Microbiol Infect 1997;3(suppl 1):S7-S20
60. Jones RN, Varnam DJ. Antimicrobial activity of broad-spectrum agents tested against gram-negative bacilli resistant to ceftazidime: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). Diagn Microbiol Infect Dis 2002;44:379-382
61. Gales AC, Jones RN, Turnidge J, Rennie R, Ramphal R. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001;32(suppl 2):S146-S155
62. Jones RN, Pfaller MA. Ciprofloxacin as broad-spectrum empiric therapy: are fluoroquinolones still viable monotherapeutic agents compared with β-lactams: data from the MYSTIC Program (US)? Diagn Microbiol Infect Dis 2002;42:213-215
63. Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gramnegative bacteria. Ann Pharmacother 1999;33:960-967
64. Gales AC, Reis AO, Jones RN. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol 2001;39:183-190
65. Burns JL, Saiman L, Whittier S, et al. Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. J Clin Microbiol 2000;38:1818-1822
66. Burns JL, Saiman L, Whittier S, et al. Comparison of two commercial systems (Vitek and MicroScan-WalkAway) for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. Diagn Microbiol Infect Dis 2001;39:257-260
67. Gales AC, Jones RN, Forward KR, Linares J, Sader HS, Verhoef J. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). Clin Infect Dis 2001;32(suppl 2):S104-S113
68. Wisplinghoff H, Edmond MB, Pfaller MA, Jones RN, Wenzel RP, Seifert H. Nosocomial blood stream infections caused by Acinetobacter species in United States hospitals: clinical features, molecular epidemiology, and antimicrobial susceptibility. Clin Infect Dis 2000;31:690-697
69. Jellison TK, McKinnon PS, Rybak MJ. Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin/sulbactam. Pharmacother 2001;21:142-148
70. Page MI. Understanding metallo-β-lactamases. ASM News 2002;68:217-221
71. Livermore DM, Woodford N. Carbapenems: a problem in waiting? Curr Opin Microbiol 2000;3:489-495
72. Nordmann P, Poirel L. Emerging carbapenemases in gramnegative aerobes. Clin Microbiol Infect 2002;8:321-331
73. Gales AC, Biedenbach DJ, Winokur P, Hacek DM, Pfaller MA,Jones RN. Carbapenem-resistant Serratia marcescens isolated producing Bush Group 2f β-lactamase (SME-1) in the United States: results from the MYSTIC Programme. Diagn Microbiol Infect Dis 2001;39:125-127
74. Kollef MH, Ward S, Sherman G, et al. Inadequate treatment of nosocomial infections is associated with certain empiric antibiotic choices. Critical Care Med 2000;28:3458-3464
75. Ambrose PG, Grasela DM. The use of Monte Carlo simulation to examine the pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2000;38:151-157
76. Ambrose PG, Owens RC Jr, Garvey MJ, Jones RN. Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime. J Antimicrob Chemother 2002;49:445-453
77. Ambrose PG, Owens RC, Grasela DM. Antimicrobial pharmacodynamics. Med Clin N Am 2000;84:1431-1445
78. Ambrose PG, Richerson MA, Stanton ME, et al. Cost-effective analysis of cefepime compared with ceftazidime in intensive care unit patients with hospital-acquired pneumoniae. Infect Dis Clin Pract 1999;8:245-251
79. Kuti JL, Nightingale CH, Quintiliani R, Nicolau DP. Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis. Diagn Microbiol Infect Dis 2002;44:51-57